Name: Xin Weisheng
Address: 5995 Huyi Road, Shanghai, AB 123C, China
Telephone: 021 5958 5480
Price range: Competitive

07 Jan 2026

2026: Putting the Reindustrialization Mandate Into Practice

Industry leaders are focused on the resilience of key starting material supply and the knock-on effects of automation in the new year.
Find out more
20 Nov 2025

J&J expands cancer portfolio with $3.05 billion Halda buy

Johnson & Johnson (JNJ.N), opens new tab said on Monday it would buy privately held Halda Therapeutics for $3.05 billion in cash, aiming to expand its presence in treatments targeting solid tumors and prostate cancer.
Find out more
22 Oct 2025

Cambrex invests $120M to expand US API, peptide manufacturing capacity

The New Jersey-based CDMO is expanding its Charles City, Iowa site to boost large-scale active pharmaceutical ingredient production and meet rising peptide demand.
Find out more
29 Sep 2025

Sartorius Stedim Biotech expands French site with GMP transfection reagent production

The facility in Illkirch more than doubles in size and adds pharmaceutical-grade reagent manufacturing for cell and gene therapy customers.
Find out more
14 Aug 2025

Trump executive order directs ASPR to secure stockpiles of critical drug APIs

The Assistant Secretary for Preparedness and Response must come up with a list of approximately 26 drugs, secure a six-month supply, and prioritize domestic sourcing.
Find out more
30 Jul 2025

Bio Usawa Biotechnology and Sartorius Partner to Boost Biopharmaceutical Manufacturing in Africa

Bio Usawa Biotechnology has formed a strategic partnership with Sartorius Stedim Biotech to advance the continent’s biopharmaceutical manufacturing capabilities.
Find out more
30 Jun 2025

Iraq aims to cover 70% of local medicine needs within two years

Baghdad (IraqiNews.com) – Iraq’s pharmaceutical localization program is projected to cover 70% of the country’s domestic medicine needs within the next two years, Hamoudi Al-Lami
Find out more
12 May 2025

Aptar CSP Technologies launches cGMP early-stage clinical manufacturing site

Aptar CSP Technologies, part of AptarGroup, has announced the expansion of its service offerings with the launch of a cGMP-compliant manufacturing facility in New Jersey.
Find out more
20 Apr 2025

Novartis to invest $23 billion in US manufacturing and research expansion

Novartis plans to invest $23 billion over the next five years to expand its U.S.-based manufacturing and research infrastructure, aiming to produce all of its key medicines domestically.
Find out more

News